eyeforpharma Philadelphia 2017: Be the trusted healthcare partner #efpPhilly

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it.

One eyeforpharma Philadelphia. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond.

The 6 sessions will focus on:

  • Commercial Leadership
    The rules of the game have changed: we have moved away from a volume approach. We must recognize that our medicine is not the asset, it is merely one of our assets - another key asset being the understanding we have of our patient's lives. Our metrics have already moved away from sales, towards engagement. Find out how pharma's c-suite are embracing the new customer engagement paradigm.
  • The Heart of Customer Experience
    Make no mistake, it's 2017 and your customers are in charge. A positive, reliable experience at any touch point will be necessary to unleash new levels of engagement, loyalty and the rewards this brings for patients as well as your business. Help your customers succeed as a partner and differentiate your company through the way you engage.
  • Commercial Model Innovation
    Your face-to-face push model has evolved in the face of healthcare consumerization and provider consolidation. It's more vital than ever to develop an effective and sustainable commercial model. Understand the market dynamics and position your teams for industry leadership.
  • Digital Transformation & Technology
    As consumers, digital is key to everything we do. To ensure that your company is leveraging the technology transformation, you must ensure that digital is integral to your business plan. Join leaders in tech and industry and develop a strategic vision to embed digital throughout the organization.
  • Pharma's 'Triple Aim': Access, affordability and adherence
    New strategies are needed to help patients manage healthcare payment concerns and adherence through better assistance and engagement services than ever before. Hear action-driven case studies about the power of empathy in guiding successful patient support.
  • Patients as partners: Co-creation and shared decision-making
    Moving from 'words to action' has been a key imperative for those who want to lead patient-centric change in our industry. Looking at both partnerships with stakeholders and initiatives from within, our sessions will help you achieve 'quick-wins' as well as big transformations. See the full agenda here.

Why you can't miss The eyeforpharma Philadelphia Summit 2017

With 15 years of experience, eyeforpharma has tailored this summit to go beyond the offerings of a normal conference. The 2017 Summit will guarantee:
  • More Than 50 Executive-level Thought Leaders sharing their experience and knowledge. Take this opportunity to transform your organisation, become truly customer-centric and improve healthcare outcomes.
  • NO Sales Pitch: this is an independently researched event committed to equipping you with the techniques and expertise to drive your business. You will take-away actionable insights proven to drive your commercial strategy.
  • 10+ Hours of Dedicated Networking: Identify new business opportunities and develop valuable and lasting relationships with senior-level executives that create partnerships and collaborations beyond what's possible in the office.
  • NEW for 2017 - Innovative Sessions that Deepen Your Thinking: From Think Tanks, to Panel Debates, to Roundtables to Fire-side Chats, we can guarantee you a variety of sessions that will help you identify the answers to common challenges commercial professionals are faced with.
  • Included in your Philly pass: eyeforpharma Philadelphia has just gotten bigger, one-pass will not gain you access to eyeforpharma's "Brand New" Medical Affairs meeting

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

For further information, please visit:
http://www.eyeforpharma.com/philadelphia/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]